Bioinformatics Combined With Biological Experiments to Identify the Pathogenetic Link of Type 2 Diabetes for Breast Cancer

Xin Bao(Shaanxi University of Chinese Medicine), Tengxiang Chen(Guiyang Medical University), Weiyun Z. Ai(City College of San Francisco), Wenjing Tang(Chinese PLA General Hospital), Shu Liu(Guangdong Province Women and Children Hospital), Qian Yang(Shanghai Jiao Tong University), Kang Chen(Chinese PLA General Hospital), Dahuan Li(University of Lausanne), Yongkang Wang(Guiyang Medical University), Zhirui Zeng(Guiyang Medical University)
Cancer Medicine
April 1, 2025
10.1002/cam4.70759
Cited by 2

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
|Journal of Clinical Oncology|2010|487
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
|The Lancet Oncology|2021|428
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|396
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2013|247